These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 25047402)

  • 1. Role of Toll-like receptors 2 and 4 in mediating endothelial dysfunction and arterial remodeling in primary arterial antiphospholipid syndrome.
    Benhamou Y; Bellien J; Armengol G; Brakenhielm E; Adriouch S; Iacob M; Remy-Jouet I; Le Cam-Duchez V; Monteil C; Renet S; Jouen F; Drouot L; Menard JF; Borg JY; Thuillez C; Boyer O; Levesque H; Richard V; Joannidès R
    Arthritis Rheumatol; 2014 Nov; 66(11):3210-20. PubMed ID: 25047402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toll-like receptor 2 controls acute immune complex-driven arthritis in mice by regulating the inhibitory Fcγ receptor IIB.
    Abdollahi-Roodsaz S; Koenders MI; Walgreen B; Bolscher J; Helsen MM; van den Bersselaar LA; van Lent PL; van de Loo FA; van den Berg WB
    Arthritis Rheum; 2013 Oct; 65(10):2583-93. PubMed ID: 23860661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiphospholipid antibody-mediated effects in an arterial model of thrombosis are dependent on Toll-like receptor 4.
    Laplante P; Fuentes R; Salem D; Subang R; Gillis MA; Hachem A; Farhat N; Qureshi ST; Fletcher CA; Roubey RA; Merhi Y; Thorin É; Levine JS; Mackman N; Rauch J
    Lupus; 2016 Feb; 25(2):162-76. PubMed ID: 26391610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insights into antiphospholipid-related endothelial dysfunction by assessment of vascular glycocalyx layer: results from a preliminary cross-sectional study.
    Miranda S; Billoir P; Le Besnerais M; Joannides R; Richard V; Lévesque H; Armengol G; Bellien J; Benhamou Y
    Lupus; 2020 Feb; 29(2):157-164. PubMed ID: 31948351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies.
    Pierangeli SS; Vega-Ostertag ME; Raschi E; Liu X; Romay-Penabad Z; De Micheli V; Galli M; Moia M; Tincani A; Borghi MO; Nguyen-Oghalai T; Meroni PL
    Ann Rheum Dis; 2007 Oct; 66(10):1327-33. PubMed ID: 17261530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome: focus on β2GPI-specific T cell response.
    Conti F; Spinelli FR; Alessandri C; Pacelli M; Ceccarelli F; Marocchi E; Montali A; Capozzi A; Buttari B; Profumo E; Sorice M; Arca M; Valesini G; Riganò R
    Arterioscler Thromb Vasc Biol; 2014 Mar; 34(3):661-8. PubMed ID: 24436371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological features of primary anti-phospholipid syndrome in connection with endothelial dysfunction.
    Soltesz P; Der H; Veres K; Laczik R; Sipka S; Szegedi G; Szodoray P
    Rheumatology (Oxford); 2008 Nov; 47(11):1628-34. PubMed ID: 18782854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome.
    Charakida M; Besler C; Batuca JR; Sangle S; Marques S; Sousa M; Wang G; Tousoulis D; Delgado Alves J; Loukogeorgakis SP; Mackworth-Young C; D'Cruz D; Luscher T; Landmesser U; Deanfield JE
    JAMA; 2009 Sep; 302(11):1210-7. PubMed ID: 19755700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow-mediated arterial dilation in primary antiphospholipid syndrome.
    Bilora F; Sartori MT; Zanon E; Campagnolo E; Arzenton M; Rossato A
    Angiology; 2009; 60(1):104-7. PubMed ID: 18388060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome.
    Der H; Kerekes G; Veres K; Szodoray P; Toth J; Lakos G; Szegedi G; Soltesz P
    Lupus; 2007; 16(7):497-503. PubMed ID: 17670848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endothelium-dependent and independent dilation capability of peripheral arteries in patients with systemic lupus erythematosus and antiphospholipid syndrome.
    Stalc M; Tomsic M; Jezovnik MK; Poredos P
    Clin Exp Rheumatol; 2011; 29(4):616-23. PubMed ID: 21813059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with antiphospholipid syndrome display endothelial perturbation.
    Cugno M; Borghi MO; Lonati LM; Ghiadoni L; Gerosa M; Grossi C; De Angelis V; Magnaghi G; Tincani A; Mari D; Riboldi P; Meroni PL
    J Autoimmun; 2010 Mar; 34(2):105-10. PubMed ID: 19656656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway.
    López-Pedrera C; Buendía P; Cuadrado MJ; Siendones E; Aguirre MA; Barbarroja N; Montiel-Duarte C; Torres A; Khamashta M; Velasco F
    Arthritis Rheum; 2006 Jan; 54(1):301-11. PubMed ID: 16385547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways.
    Grabig A; Paclik D; Guzy C; Dankof A; Baumgart DC; Erckenbrecht J; Raupach B; Sonnenborn U; Eckert J; Schumann RR; Wiedenmann B; Dignass AU; Sturm A
    Infect Immun; 2006 Jul; 74(7):4075-82. PubMed ID: 16790781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Markers of cardiovascular risk in patients with antiphospholipid syndrome: a meta-analysis of literature studies.
    Ambrosino P; Lupoli R; Di Minno A; Iervolino S; Peluso R; Di Minno MN
    Ann Med; 2014 Dec; 46(8):693-702. PubMed ID: 25307359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells.
    Pierangeli SS; Harris EN
    Lupus; 2003; 12(7):539-45. PubMed ID: 12892395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome.
    Redecha P; Franzke CW; Ruf W; Mackman N; Girardi G
    J Clin Invest; 2008 Oct; 118(10):3453-61. PubMed ID: 18802482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating plasmablasts contribute to antiphospholipid antibody production, associated with type I interferon upregulation.
    Hisada R; Kato M; Sugawara E; Kanda M; Fujieda Y; Oku K; Bohgaki T; Amengual O; Horita T; Yasuda S; Atsumi T
    J Thromb Haemost; 2019 Jul; 17(7):1134-1143. PubMed ID: 30864219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The involvement of CD36 in monocyte activation by antiphospholipid antibodies.
    Kato M; Atsumi T; Oku K; Amengual O; Nakagawa H; Fujieda Y; Otomo K; Horita T; Yasuda S; Koike T
    Lupus; 2013 Jul; 22(8):761-71. PubMed ID: 23817509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome.
    Bontadi A; Ruffatti A; Falcinelli E; Giannini S; Marturano A; Tonello M; Hoxha A; Pengo V; Punzi L; Momi S; Gresele P
    Thromb Haemost; 2013 May; 109(5):901-8. PubMed ID: 23572134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.